<- Go Home

Bionano Genomics, Inc.

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. The company offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. It also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic data from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, the company offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Market Cap

$11.2M

Volume

80.2K

Cash and Equivalents

$3.6M

EBITDA

-$45.3M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$494.0K

Profit Margin

1.74%

52 Week High

$72.60

52 Week Low

$2.68

Dividend

N/A

Price / Book Value

0.24

Price / Earnings

-0.08

Price / Tangible Book Value

0.29

Enterprise Value

$11.4M

Enterprise Value / EBITDA

-0.27

Operating Income

-$58.7M

Return on Equity

127.82%

Return on Assets

-31.04

Cash and Short Term Investments

$18.2M

Debt

$18.4M

Equity

$48.2M

Revenue

$28.5M

Unlevered FCF

$1.8M

Sector

Life Sciences Tools and Services

Category

N/A

Company Stock Pitches